INT353109

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.02
First Reported 2007
Last Reported 2007
Negated 0
Speculated 2
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 3.93
Pain Relevance 0.43

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (VEGFA) growth (VEGFA) extracellular region (VEGFA)
proteinaceous extracellular matrix (VEGFA) nucleus (Aes) cytoplasm (VEGFA)
VEGFA (Homo sapiens)
Aes (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 48 90.36 High High
cva 34 87.04 High High
Inflammatory response 2 47.20 Quite Low
cytokine 2 5.00 Very Low Very Low Very Low
eye pain 2 5.00 Very Low Very Low Very Low
anesthesia 2 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
ischemia 2 5.00 Very Low Very Low Very Low
Nicotine 2 5.00 Very Low Very Low Very Low
Inflammatory stimuli 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Ocular Toxicity (including Many Sub-types) 96 100.00 Very High Very High Very High
Endophthalmitis 12 92.56 High High
Uveitis 4 91.20 High High
Ocular Injury 26 90.48 High High
INFLAMMATION 56 90.36 High High
Retinal Perforations 12 88.88 High High
Cataract 14 85.04 High High
Ocular Hypertension 24 82.24 Quite High
Age-related Macular Degeneration 490 5.00 Very Low Very Low Very Low
Nicotine Addiction 24 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Through month 12 of PIER, there were no reported serious ocular AEs potentially related to intravitreal injection and no nonocular AEs that might be associated with anti-VEGF therapy as a class (Genentech, Inc. unpublished data).
VEGF Spec (might) Binding (associated) of AEs associated with ocular toxicity (including many sub-types)
1) Confidence 0.02 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012443 Disease Relevance 1.95 Pain Relevance 0.21
Through month 12 of PIER, there were no reported serious ocular AEs potentially related to intravitreal injection and no nonocular AEs that might be associated with anti-VEGF therapy as a class (Genentech, Inc. unpublished data).
VEGF Spec (might) Binding (associated) of AEs associated with ocular toxicity (including many sub-types)
2) Confidence 0.01 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012443 Disease Relevance 1.98 Pain Relevance 0.22

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox